<DOC>
	<DOCNO>NCT02594371</DOCNO>
	<brief_summary>To determine safety tolerability Oraxol compare IV paclitaxel metastatic breast cancer</brief_summary>
	<brief_title>Ph3 Study To Determine Safety , Tolerability &amp; Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase 3 , open-label , randomize , multicenter study approximately 360 adult female subject histologically- cytologically-confirmed breast cancer metastatic treatment IV paclitaxel monotherapy recommend oncologist . Approximately 400 subject enrol provide 360 evaluable subject . The subject must measurable metastatic target lesion disease per RECIST v1.1 criterion . Subjects randomize 2:1 ratio either Oraxol IV paclitaxel ( Taxol generic ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Signed write informed consent 2 . Women ≥18 year age 3 . Histologically cytologicallyconfirmed breast cancer IV paclitaxel ( Taxol generic ) monotherapy recommend oncologist 4 . Measurable metastatic target lesion disease per RECIST v1.1 criterion 5 . Adequate hematological status 6 . Adequate liver function 7 . Adequate renal function 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 9 . Life expectancy least 6 month 10 . Subjects must postmenopausal ( ≥12 month without menses ) surgically sterile ( ie , hysterectomy and/or bilateral oophorectomy ) must use effective contraception 11 . Subjects childbearing potential must negative screen serum pregnancy test . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Have recover ≤ Grade 1 toxicity previous anticancer treatment previous investigational product ( IPs ) 2 . Central nervous system metastasis , include leptomeningeal involvement 3 . Are currently receive medication intend treatment malignancy 4 . Received radiation therapy within 2 week prior sign inform consent radiation therapy plan within 6 month time sign informed consent 5 . Women pregnant breastfeed 6 . Uncontrolled intercurrent illness 7 . Known allergic reaction intolerance contrast medium 8 . Documented history true systemic allergic reaction 3 medication 9 . For Investigator believe participation study would acceptable</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>